van Boxtel W, Bulten B F, Mavinkurve-Groothuis A M C, Bellersen L, Mandigers C M P W, Joosten L A B, Kapusta L, de Geus-Oei L F, van Laarhoven H W M
Department of Medical Oncology and.
Biomarkers. 2015 Mar;20(2):143-8. doi: 10.3109/1354750X.2015.1040839. Epub 2015 May 18.
Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines.
Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines.
29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = -0.564, p ≤ 0.01).
The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.
评估多种生物标志物组合（N末端脑钠肽前体、肿瘤坏死因子-α、半乳糖凝集素-3、白细胞介素-6、肌钙蛋白I、ST2和可溶性血管内皮生长因子受体-1）以检测蒽环类药物治疗后的亚临床心脏毒性。
对55例乳腺癌患者在接受蒽环类药物治疗一年后评估生物标志物并进行超声心动图检查。
29.1%的患者生物标志物水平异常：N末端脑钠肽前体为18.2%，肿瘤坏死因子-α和半乳糖凝集素-3为7.3%。所有患者的白细胞介素-6、肌钙蛋白I、ST2和可溶性血管内皮生长因子受体-1均正常。观察到左心室射血分数（LVEF）与N末端脑钠肽前体之间存在相关性（r = -0.564，p≤0.01）。
所评估的生物标志物无助于早期检测。未来的研究应聚焦于N末端脑钠肽前体。
